Epilepsy
📧 Sign up to get email alerts when something new happens for Epilepsy.
Sign up freeTop drugs studied for this disease
-
FDA label_change · 2025-02-18FDA Approved: GABAPENTIN — Supplemental Application (American Health Packaging)
FDA approved a supplemental application for Gabapentin (generic) submitted by American Health Packaging, indicating a labeling change for th…
-
CLINICAL_TRIALS research · 2025-02-18Clinical Trial Update: Determinants of Adaptive Behavior Through the Vineland Scale in Pediatric Patients With Severe and Drug-resistant Epilepsy
This completed clinical trial examined determinants of adaptive behavior in pediatric patients with severe, treatment-resistant epilepsy usi…
-
CLINICAL_TRIALS trial_result · 2025-02-18Clinical Trial Update: Severity: Quantifying the Severity of Generalized Tonic-clonic Seizures (GTCS) With Connected Devices
A completed clinical trial evaluated methods to quantify the severity of generalized tonic-clonic seizures using connected devices. The stud…
-
CLINICAL_TRIALS research · 2025-02-17Clinical Trial Update: Evaluation of the Incidence of Psychiatric Disorders As a Function of First-line Antiepileptic Drug Prescribing Practices: Use of Assurance Maladie Databases
This clinical trial registry entry describes a planned observational study evaluating whether first-line antiepileptic drug prescribing prac…
-
FDA approval · 2025-02-14FDA Approved: LEVETIRACETAM — Supplemental Application (Lupin Pharmaceuticals, Inc.)
The FDA approved a supplemental application for levetiracetam from Lupin Pharmaceuticals, expanding/modifying the labeling for this product.…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2025-02-14FDA Approved: OXCARBAZEPINE — Supplemental Application (Bionpharma Inc.)
FDA approved a supplemental application for oxcarbazepine from Bionpharma Inc., granting additional authorization under ANDA 209652.
-
FDA approval · 2025-02-14FDA Approved: LEVETIRACETAM — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin Pharmaceuticals' supplemental application for levetiracetam, updating the product's labeling/indications.
-
CLINICAL_TRIALS research · 2025-02-14Clinical Trial Update: Status Epilepticus Population Study (STEPS)
The STEPS study is a status epilepticus population trial that is currently recruiting at University Hospital Basel, focusing on epileptic se…
-
CLINICAL_TRIALS trial_result · 2025-02-13Clinical Trial Update: Lemborexant Treatment of Insomnia Linked to Epilepsy [Phase 3]
Phase 3 clinical trial evaluating lemborexant for insomnia linked to epilepsy; the study is currently recruiting.
-
CLINICAL_TRIALS research · 2025-02-13Clinical Trial Update: An Observational Study of Epilepsy: Biology and Outcomes Using Real-world Data
An observational study examining epilepsy biology and patient outcomes using real-world data is currently recruiting.
-
CLINICAL_TRIALS research · 2025-02-12Clinical Trial Update: Sensory Modulation in Children With Epilepsy
A clinical trial from Abant Izzet Baysal University is investigating sensory modulation in children with epilepsy and sensory modulation dis…
-
CLINICAL_TRIALS research · 2025-02-11Clinical Trial Update: Sensory Perception in Children With Epilepsy
A clinical trial update shows a study evaluating sensory perception in children with epilepsy and is not yet recruiting.
-
FDA approval · 2025-02-10FDA Approved: LEVETIRACETAM — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approves a supplemental application for levetiracetam from Mylan Pharmaceuticals Inc., resulting in approval of a generic product. This …
-
FDA approval · 2025-02-10FDA Approved: LEVETIRACETAM — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental application for Levetiracetam submitted by Mylan Pharmaceuticals Inc.
-
FDA approval · 2025-02-07FDA Approved: OXCARBAZEPINE — Supplemental Application (NorthStar RxLLC)
FDA approved a supplemental application for Oxcarbazepine by NorthStar RxLLC (ANDA216749).
-
FDA approval · 2025-02-07FDA Approved: OXCARBAZEPINE — Supplemental Application (Amneal Pharmaceuticals LLC)
The FDA approved a supplemental application for oxcarbazepine from Amneal Pharmaceuticals LLC under ANDA202961.
-
CLINICAL_TRIALS research · 2025-02-07Clinical Trial Update: Effect of Cognitive Behavioral Play Intervention and Epilepsy [NA]
This clinical trial update covers a study on the effects of a Cognitive Behavioral Play Intervention for epilepsy, including pediatric epile…
-
CLINICAL_TRIALS research · 2025-02-07Clinical Trial Update: Improving Diagnostics and Care After First Seizure
This clinical trial update from Haukeland University Hospital notes recruitment for a study aimed at improving diagnostics and care after a …
-
FDA approval · 2025-02-05FDA Approved: LEVETIRACETAM — Supplemental Application (BluePoint Laboratories)
FDA approved a supplemental application from BluePoint Laboratories for levetiracetam, authorizing approval of a generic version of the anti…
-
FDA approval · 2025-02-05FDA Approved: LEVETIRACETAM — Supplemental Application (Torrent Pharmaceuticals Limited)
The FDA approved Torrent Pharmaceuticals Limited's supplemental application for levetiracetam, approving its generic product under an ANDA. …
-
CLINICAL_TRIALS research · 2025-02-04Clinical Trial Update: The Effect of Dual Task on Postural Control in Children Diagnosed with Epilepsy [NA]
This document provides an update on a completed clinical trial investigating how performing a dual task affects postural control in children…
-
CLINICAL_TRIALS trial_result · 2025-02-04Clinical Trial Update: EpiWatch: Evaluation of a Non-EEG Physiological Signal Based Seizure Monitoring System [NA]
A completed evaluation of EpiWatch, a non-EEG physiological signal-based seizure monitoring system for epilepsy with tonic-clonic seizures.
-
CLINICAL_TRIALS trial_result · 2025-02-03Clinical Trial Update: Self-management for People with Epilepsy [NA]
A completed clinical trial evaluating a self-management program for people with epilepsy.
-
CLINICAL_TRIALS trial_result · 2025-01-31Clinical Trial Update: Impact of Pharmacist-led Cognitive Behavioral Intervention on Adherence and Quality of Life of Epileptic Patients [NA]
A completed clinical trial evaluating whether a pharmacist-led cognitive behavioral intervention improves medication adherence and quality o…
-
FDA approval · 2025-01-29FDA Approved: BRIVARACETAM — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for BRIVARACETAM from Aurobindo Pharma Limited under an ANDA.